Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2126)

DELAY IN DESPATCH OF CIRCULAR

Reference is made to the announcement of JW (Cayman) Therapeutics Co. Ltd (the "**Company**") dated November 9, 2026 regarding the very substantial disposal in relation to the License and Assignment Agreement (the "**Announcement**"). Unless otherwise defined, capitalized terms used herein shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, a circular (the "**Circular**") containing, among other things, further details of the License and Assignment Agreement and the transactions contemplated thereunder and a notice of the EGM will be despatched to the Shareholders in accordance with the Listing Rules. As additional time is required for the Company to prepare and finalize certain information to be included in the Circular, the Company now expects to despatch the Circular on or before December 10, 2026.

By order of the Board
JW (Cayman) Therapeutics Co. Ltd
藥明巨諾（開曼）有限公司*
Feng Tian
Chairman and Chief Executive Officer

Shanghai, PRC, November 23, 2026

As at the date of this announcement, the Board comprises Mr. Feng Tian as Chairman and executive Director, Dr. Yiping James Li, and Ms. Xing Gao as non-executive Directors, and Mr. Kin Cheong Kelvin Ho, Dr. Debra Yu and Mr. Peng Kuan Chan as independent non-executive Directors.

* *For identification purposes only*